AUG 13, 2021 7:30 AM PDT

Breast Cancer Drug Reverses Deadly Blood Cancer in Mice

WRITTEN BY: Annie Lennon

A drug currently used to treat advanced breast cancers may treat a rare type of leukemia known as myelofibrosis. The study was published in Cancer Research by scientists at the University of Virginia Health System. 

Myelofibrosis is a form of leukemia- cancer of the blood and bone marrow. It typically occurs in those who are middle-aged or older and affects between 1 and 1.5 in every 100,000 people. Those with advanced stages of the disease have a median survival time of 1.5 to 2.3 years. 

Ruxolitinib, a kinase inhibitor, is used to relieve symptoms of the disease. The drug, however, does not address the disease's characteristic feature, bone marrow scarring. Scarring both disrupts the marrow's production of red blood cells- causing severe anemia- and reduces the number of platelets in the blood, making clotting difficult and enlarging the spleen. 

Previous studies have found that palbociclib, a cyclin-dependent kinase (CDK) inhibitor, reduces activity in the bone marrow of patients with advanced stages of breast cancer. Researchers thus sought to see how patients with myelofibrosis would respond to the drug.

In experiments involving mouse models of myelofibrosis, the researchers showed that palbociclib was able to reduce bone marrow scarring. It also decreased excessive levels of white blood cells and shrank their enlarged spleens. 

They then found that, when combined with ruxolitinib, palbociclib was able to restore bone marrow in mice, normalize white blood cell counts, and further reduce the size of enlarged spleens. 

"A combinatorial therapeutic approach involving palbociclib and ruxolitinib will enable lowering the doses of each of the inhibitors and thus reducing toxicities while enhancing the therapeutic efficacy," wrote the researchers in their paper. 

"The findings from this study are very exciting, and they support the clinical investigation of palbociclib and ruxolitinib combination in patients with myelofibrosis," said Golam Mohi, one of the authors of the paper. 

 

Sources:  Cancer ResearchMPN ConnectScience Daily

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
AUG 11, 2021
Neuroscience
Beige Fat Cells Protect the Brain from Dementia
AUG 11, 2021
Beige Fat Cells Protect the Brain from Dementia
‘Beige’ fat reduces inflammation in mouse brains, and may provide protection from dementia. The correspondin ...
AUG 13, 2021
Cancer
Ultrasound Triggers Immunotherapy to Destroy Tumors
AUG 13, 2021
Ultrasound Triggers Immunotherapy to Destroy Tumors
An immunotherapy engineered to be triggered by ultrasound beams significantly slows the growth of cancerous tumors in mi ...
AUG 18, 2021
Neuroscience
Histamine Regulates Serotonin Levels in Depression
AUG 18, 2021
Histamine Regulates Serotonin Levels in Depression
Heightened histamine levels from inflammation inhibit the effects of the mood-regulating neurotransmitter serotonin in t ...
AUG 31, 2021
Drug Discovery & Development
A drug-free rehabilitation system for stroke survivors.
AUG 31, 2021
A drug-free rehabilitation system for stroke survivors.
     Last week, the United States Food and Drug Administration (FDA) approved a first-of-its-kind&nb ...
SEP 07, 2021
Drug Discovery & Development
A giant step in treating growth disorders in children.
SEP 07, 2021
A giant step in treating growth disorders in children.
Hormone production and release is important in individuals of all ages but is especially important for children as hormo ...
SEP 16, 2021
Drug Discovery & Development
A shot for sore eyes: a novel injectable drug to treat age-related vision loss
SEP 16, 2021
A shot for sore eyes: a novel injectable drug to treat age-related vision loss
According to the Population Reference Bureau, 40 million people in the United States are aged 65 and older. This nu ...
Loading Comments...